IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 71.54

Change

+0.42 (+0.59)%

Market Cap

N/A

Volume

0.06M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.79 (-0.54%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

-0.43 (-0.62%)

USD 2.77B
FXH First Trust Health Care AlphaD..

-0.90 (-0.83%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-1.49 (-1.63%)

USD 0.20B
IDNA iShares Genomics Immunology an..

N/A

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.08 (+0.26%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-3.71 (-3.64%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.64 (-2.10%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.54 (-0.85%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.40 (-1.81%)

USD 6.67M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.86% 90% A- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.86% 90% A- 87% B+
Trailing 12 Months  
Capital Gain 2.86% 62% D 45% F
Dividend Return 1.33% 88% B+ 23% F
Total Return 4.20% 67% D+ 35% F
Trailing 5 Years  
Capital Gain 34.18% 71% C- 66% D+
Dividend Return 8.88% 95% A 27% F
Total Return 43.06% 76% C+ 63% D
Average Annual (5 Year Horizon)  
Capital Gain 4.12% 48% F 47% F
Dividend Return 5.51% 57% F 45% F
Total Return 1.39% 100% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 15.33% 71% C- 65% D
Risk Adjusted Return 35.94% 67% D+ 50% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike